Emergent BioSolutions swung from $51.2 million in profit to a $32.7 million loss.
Emergent BioSolutions reported a Q3 2026 net loss of $32.7 million, down from a $51.2 million profit in Q3 2025. Revenues fell 52% to $110 million. The company cited decreased sales in Naloxone, Smallpox MCM, and Other Products, while Anthrax MCM revenues increased. Operating expenses decreased slightly, but SG&A expenses rose. The CFO announced retirement, and a $75 million debt repurchase was completed. The company secured a $24 million contract modification for its Anthrax vaccine.
How this was made
The 30-second read
Why it matters
The earnings miss is likely to weigh on the stock in the short term, though new contracts could mitigate longer‑term concerns.
Market read
Primary earnings disclosure for a mid‑cap biotech; immediate price impact expected.
What to watch
Awarded a $24M contract modification for CYFENDUS® and a standing offer for NARCAN® may provide future revenue tailwinds.
Background
Emergent BioSolutions reported its Q3 2026 financial results, highlighting a loss, margin compression, and recent contract wins.
Ticker impact
Q3 2026 earnings show a swing to a $32.7M loss and a 30% net margin, a fresh primary disclosure for Emergent BioSolutions.
downward pressure as investors price the unexpected loss and margin decline
The company posted a sizable loss versus a prior profit, with lower gross margins and higher SG&A, which typically depresses the stock.
Market effects
Defence‑biotech sector may see broader scrutiny as earnings miss highlights margin pressure.
US biotech stocks could face short‑term weakness.
Limited to investors tracking US‑listed biotech and government contract exposure.
Counterpoint
The loss is driven by one‑off restructuring costs; upcoming contract modifications and new growth organization could support a rebound.
Key entities
- companyEmergent BioSolutions
US‑listed biotech firm focused on counter‑bioterrorism and opioid overdose products.
